| High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse S Shalapour, J Hof, R Kirschner-Schwabe, L Bastian, C Eckert, J Prada, ... Haematologica 96 (11), 1627, 2011 | 89 | 2011 |
| PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia L Bastian, MP Schroeder, C Eckert, C Schlee, JO Tanchez, S Kämpf, ... Leukemia 33 (8), 1895-1909, 2019 | 60 | 2019 |
| Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB L Bastian, J Hof, M Pfau, I Fichtner, C Eckert, G Henze, J Prada, ... Clinical Cancer Research 19 (6), 1445-1457, 2013 | 51 | 2013 |
| Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia AR James, MP Schroeder, M Neumann, L Bastian, C Eckert, N Gökbuget, ... Journal of Hematology & Oncology 12 (1), 1-16, 2019 | 39 | 2019 |
| Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures MP Schroeder, L Bastian, C Eckert, N Gökbuget, AR James, JO Tanchez, ... Scientific reports 9 (1), 4188, 2019 | 32 | 2019 |
| Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL K Müller, F Vogiatzi, D Winterberg, T Rösner, L Lenk, L Bastian, ... Blood, The Journal of the American Society of Hematology 140 (1), 45-57, 2022 | 29 | 2022 |
| Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL L Fransecky, M Neumann, S Heesch, C Schlee, J Ortiz-Tanchez, S Heller, ... Journal of Hematology & Oncology 9 (1), 1-12, 2016 | 29 | 2016 |
| UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment L Bastian, AM Hartmann, T Beder, S Hänzelmann, J Kässens, ... Leukemia 36 (6), 1676-1680, 2022 | 19 | 2022 |
| The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age T Beder, BT Hansen, AM Hartmann, J Zimmermann, E Amelunxen, ... HemaSphere 7 (9), e939, 2023 | 16* | 2023 |
| In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets M Carlet, K Völse, J Vergalli, M Becker, T Herold, A Arner, D Senft, ... Nature communications 12 (1), 5655, 2021 | 14 | 2021 |
| Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab N Baumann, C Arndt, J Petersen, M Lustig, T Rösner, K Klausz, C Kellner, ... Frontiers in Immunology 13, 949140, 2022 | 12 | 2022 |
| The sequence of application of methotrexate and histone deacetylase inhibitors determines either a synergistic or an antagonistic response in childhood acute lymphoblastic … L Bastian, HG Einsiedel, G Henze, K Seeger, S Shalapour Leukemia 25 (2), 359-361, 2011 | 11 | 2011 |
| Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells M Lustig, C Chan, JH Jansen, M Bräutigam, MA Kölling, CL Gehlert, ... Frontiers in Immunology 14, 1178817, 2023 | 10 | 2023 |
| Development of an Epstein–Barr virus‐associated lymphoproliferative disorder in a patient treated with azacitidine for chronic myelomonocytic leukaemia T Menter, M Schlageter, L Bastian, R Haberthür, AE Rätz Bravo, ... Hematological oncology 32 (1), 47-51, 2014 | 10 | 2014 |
| Irf4 deficiency vulnerates b-cell progeny for leukemogenesis via somatically acquired jak3 mutations conferring il-7 hypersensitivity D Das Gupta, C Paul, N Samel, M Bieringer, D Staudenraus, F Marini, ... Cell Death & Differentiation 29 (11), 2163-2176, 2022 | 9 | 2022 |
| Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL L Bastian, T Beder, MJ Barz, S Bendig, L Bartsch, W Walter, N Wolgast, ... Blood 143 (14), 1391-1398, 2024 | 7 | 2024 |
| Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation J Lázaro-Navarro, HJ Pimentel-Gutiérrez, A Gauert, AIH Hagemann, ... Blood Advances 5 (24), 5501-5506, 2021 | 7 | 2021 |
| Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML) S Steinhäuser, P Silva, L Lenk, T Beder, A Hartmann, S Hänzelmann, ... Leukemia 37 (1), 134-142, 2023 | 6 | 2023 |
| Chemotherapy‐induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancer G Hugendieck, M Lettau, S Andreas, S Neumann, N Reinhardt, P Arnold, ... Journal of Extracellular Vesicles 12 (7), 12338, 2023 | 5 | 2023 |
| Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia G Chitadze, A Stengel, C John-Klaua, J Bruckmüller, H Trautmann, ... Blood 141 (13), 1640-1644, 2023 | 5 | 2023 |
Claudia BaldusUKSH, Kiel, Germany在 uksh.de 的电子邮件经过验证
